Skip to main content
Figure 5 | BMC Medical Genomics

Figure 5

From: The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel

Figure 5

Decreased NRF2 expression alters tumor cell response to arsenic trioxide. Cells (A549 lung carcinoma) deficient for the expression of NRF2 (NRF2-KD), a scramble shRNA control (scramble), a turbo-GFP control (GFP) were generated using shRNAs and tested for their sensitivity to arsenic trioxide. (A) Cells expressing the NRF2-shRNA have decreased mRNA expression of NRF2 relative to the controls; (B) Cells expressing the NRF2-shRNA have decreased mRNA expression of NQO1, a well known NRF2 target gene; (C) Cells expressing the NRF2-shRNA show no alterations in mRNA expression of β-ACTIN; (D) Cells with decreased expression levels of NRF2 show increased sensitivity to arsenic trioxide induced killing.

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us